2252 Stock Overview
Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 2252 from our risk checks.
Shanghai RAAS Blood Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.07 |
| 52 Week High | CN¥8.68 |
| 52 Week Low | CN¥5.93 |
| Beta | 0.43 |
| 1 Month Change | 0.28% |
| 3 Month Change | 3.21% |
| 1 Year Change | 14.77% |
| 3 Year Change | -11.07% |
| 5 Year Change | -16.13% |
| Change since IPO | 652.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2252 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 3.5% | 0.3% | 1.6% |
| 1Y | 14.8% | -24.2% | -15.1% |
Return vs Industry: 002252 exceeded the CN Biotechs industry which returned -24.2% over the past year.
Return vs Market: 002252 exceeded the CN Market which returned -15.1% over the past year.
Price Volatility
| 2252 volatility | |
|---|---|
| 2252 Average Weekly Movement | 3.9% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 002252 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002252's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 3,121 | Jun Xu | www.raas-corp.com |
Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products.
Shanghai RAAS Blood Products Co., Ltd. Fundamentals Summary
| 2252 fundamental statistics | |
|---|---|
| Market cap | CN¥46.98b |
| Earnings (TTM) | CN¥2.06b |
| Revenue (TTM) | CN¥7.55b |
22.8x
P/E Ratio6.2x
P/S RatioIs 2252 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2252 income statement (TTM) | |
|---|---|
| Revenue | CN¥7.55b |
| Cost of Revenue | CN¥4.41b |
| Gross Profit | CN¥3.14b |
| Other Expenses | CN¥1.08b |
| Earnings | CN¥2.06b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | 0.31 |
| Gross Margin | 41.62% |
| Net Profit Margin | 27.33% |
| Debt/Equity Ratio | 0% |
How did 2252 perform over the long term?
See historical performance and comparison